Table 2.
Change in biomarker measurements and select vital signs from randomization to week 12 for patients in the per-protocol population
| Placebo |
Etoricoxib |
Celecoxib |
Ibuprofen |
|||||
|---|---|---|---|---|---|---|---|---|
| N | Mean (SD) | N | Mean (SD) | N | Mean (SD) | N | Mean (SD) | |
| Measurements of Biomarkers Throughout the Study Duration | ||||||||
| CRP (mg/L) | ||||||||
| Randomization | 111 | 5.4 (6.0) | 108 | 4.6 (6.1) | 107 | 6.0 (6.9) | 106 | 5.2 (5.8) |
| Week 12 | 70 | 5.2 (6.1) | 72 | 4.0 (4.6) | 76 | 4.6 (5.3) | 79 | 4.4 (5.4) |
| LDL-C (mg/dL) | ||||||||
| Randomization | 110 | 127.2 (37.6) | 108 | 121.2 (28.7) | 107 | 131.1 (34.8) | 105 | 124.8 (30.9) |
| Week 12 | 69 | 123.2 (29.5) | 72 | 115.5 (29.2) | 76 | 127.7 (34.4) | 79 | 124.2 (30.9) |
| Homocysteine (µmol/L) | ||||||||
| Randomization | 111 | 9.0 (3.0) | 107 | 8.9 (3.0) | 107 | 9.6 (9.1) | 107 | 9.2 (2.6) |
| Week 12 | 71 | 8.9 (2.7) | 72 | 8.8 (3.2) | 76 | 8.6 (2.4) | 79 | 9.3 (2.9) |
| Fibrinogen (mg/dL) | ||||||||
| Randomization | 110 | 418.5 (81.7) | 107 | 409.8 (84.5) | 107 | 420.6 (86.7) | 106 | 410.3 (82.7) |
| Week 12 | 71 | 413.0 (85.3) | 73 | 388.1 (87.8) | 76 | 396.6 (86.1) | 78 | 386.6 (74.8) |
| Measurements of Blood Pressure and Body Weight Throughout the Study Duration | ||||||||
| Systolic Blood Pressure | ||||||||
| Randomization | 67 | 125.5 (31.1) | 69 | 126.7 (14.2) | 63 | 128.3 (13.0) | 73 | 127.1 (14.4) |
| Week 12 | 67 | 126.7 (14.4) | 69 | 130 (14.9) | 63 | 131.8 (14.4) | 73 | 127.8 (16.2) |
| Diastolic Blood Pressure | ||||||||
| Randomization | 67 | 78.3 (7.7) | 69 | 77.2 (7.1) | 63 | 77.3 (7.0) | 73 | 79.2 (8.0) |
| Week 12 | 67 | 78.9 (9.0) | 69 | 78.3 (9.2) | 63 | 78.3 (7.9) | 73 | 77.1 (8.2) |
| Weight (lb) | ||||||||
| Randomization | 67 | 186.3 (43.2) | 69 | 188.9 (47.1) | 63 | 205.5 (44.8) | 71 | 186.2 (36.4) |
| Week 12 | 67 | 186.6 (43.0) | 69 | 190.8 (47.6) | 63 | 205.4 (44.3) | 71 | 188.9 (37.2) |